




UNITED STATES PATENT AND TRADEMARK OFFICE

JPLW
COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

60849

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

1m. 6. 4. 01
2m. 7. 4. 01
3m. 8. 4. 01
4m. 9. 4. 01
5m. 10. 4. 01
6m. 11. 4. 01

AP

RECEIVED

JUN 11 2001

TECH CENTER 1600 2900

RECEIVED
COMMUNICATIONS SECTION

MAY - 7 2001

DOCKET CLERK

EXAMINER

Bronwen M. Loeb

ART UNIT

PAPER

1636

13

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents


The communication filed April 3, 2001 is not fully responsive to the Office communication mailed March 6, 2001 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CFR Diskette Problem Report. Applicant must comply with the requirements of the sequences rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the reply appears to a bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a **TIME PERIOD** of **ONE (1) MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821 (g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Bronwen M. Loeb, Art Unit 1636, whose telephone number is (703) 605-1197.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

ROBERT A. SCHWARTZMAN
PRIMARY EXAMINER



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 11 2001

Applicants: Paul B. Fisher, et al.

Serial No.: 09/515,363

Filed : February 29, 2000

TECH CENTER 1600 2900

For : MELANOMA DIFFERENTIATION ASSOCIATED GENE-5
(Mda-5), PROMOTER AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
June 1, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)
IN CONNECTION WITH ABOVE-IDENTIFIED APPLICATION

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the enclosed computer readable form (CRF) containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) has the same information as the paper copy of the Sequence Listing submitted herewith as **Exhibit B** in connection with the subject application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Alexander P. Errico
c/o Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400